TransEnterix Announces First Pediatric Surgical Cases with Senhance® Surgical System
October 13 2020 - 6:55AM
Business Wire
Pediatric Patients Successfully Treated
Utilizing 3mm Instruments on Digital Laparoscopy Platform
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that surgeons at Maastricht University Medical Center+ (MUMC+) in
the Netherlands, have successfully operated on multiple pediatric
patients, becoming the first pediatric surgical program in the
world to utilize the Senhance® Surgical System and integrate
digital laparoscopy with instruments as small as 3 mm into their
standard of surgical care.
“Pediatric surgery is a field that demands precision, control
and minimal invasiveness. The Senhance System is designed to
maximize control of instruments as small as 3 mm and be compatible
with small scopes while also retaining the sense of touch through
haptic feedback,” said Anthony Fernando, President and Chief
Executive Officer of TransEnterix. “This is the first time that 3
mm instruments have been used in robotic pediatric surgery and
MUMC+ is the first hospital to initiate a pediatric surgery program
with Senhance. We will continue to work with their excellent
surgeons to build a successful clinical program and grow the
adoption of Senhance in pediatric surgery.”
“The ability to use 3 mm instruments on a robotic platform is
what first drew my team to utilize the Senhance,” said Prof. Dr.
Wim van Gemert, Chairman of the Department of Pediatric Surgery,
MUMC+. “As we have begun to utilize the Senhance System in multiple
pediatric patients, including complex reconstructive procedures,
we’ve found that the haptic feedback, precision and unique vision
control system are advantages to our experience. This platform has
a very promising future as a tool in the hands of pediatric
surgeons.”
The Senhance Surgical System is the first and only digital
laparoscopic platform designed to maintain laparoscopic minimally
invasive surgery standards while providing digital benefits such as
haptic feedback, robotic precision, eye-sensing camera control,
comfortable ergonomics, advanced instrumentation including 3 mm
microlaparoscopic instruments, and reusable standard instruments to
help maintain per-procedure costs similar to traditional
laparoscopy.
Senhance European Indication for Use
The Senhance Surgical System has received a CE Mark according to
the Medical Device Directive and is intended to be used for
laparoscopic surgery in the abdomen, pelvis and limited uses in the
thoracic cavity excluding the heart and greater vessels. The system
is indicated for adult and pediatric use in CE marked
territories.
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new Intelligent Surgical Unit™ (ISU™) that enables
augmented intelligence in surgery. The Senhance Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, and select other countries. For a
complete list of indications for use, please visit:
https://www.transenterix.com/indications-for-use/.
About Maastricht University Medical Center+
MUMC+ is known both nationally and internationally for its focus
on prevention and taking an integrated approach to health care:
from prevention, promotion of good health, and basic care, to
top-level clinical diagnostics and treatment. Patient safety is our
top priority in all of our endeavours. MUMC+ has 715 beds and
approximately 7,000 employees and 4,000 students. MUMC+ is part of
The Netherlands Federation of University Medical Centres.
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and the first pediatric surgical program with the
Senhance Surgical System. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether TransEnterix will continue to work with the
excellent surgeons of MUMC+ to build a successful clinical program
and grow the adoption of the Senhance System in pediatric surgery
and whether the Senhance System has a very promising future as a
tool in the hands of pediatric surgeons . For a discussion of the
risks and uncertainties associated with TransEnterix's business,
please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K for the
year ended December 31, 2019, filed with the SEC on March 16, 2020
and our other filings we make with the SEC. You are cautioned not
to place undue reliance on these forward looking statements, which
are based on our expectations as of the date of this press release
and speak only as of the origination date of this press release. We
undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201013005163/en/
Investor Contact: Mark Klausner, +1 443-213-0501
invest@transenterix.com or Media Contact: Terri Clevenger, +1
203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Sep 2023 to Sep 2024